Alison S. Rustagi

Alison S. Rustagi

Auto-generated profile, based on publicly available information

Alison S. Rustagi

Center for Data to Discovery and Delivery Innovation (3DI), San Francisco VA Health Care System, San Francisco, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ARAlison S. Rustagi
Alison S. Rustagi
ABAmy L. Byers
Amy L. Byers
SKSalomeh Keyhani
Salomeh Keyhani
Lung cancer is the leading cause of cancer deaths in the US.1 From 2013 to 2021, the US Preventive Services Task Force recommended lung cancer screening (LCS) via low-dose computed tomography for adults aged 55 to 80 years with a greater than or equal to 30 pack-year history who are current smokers or quit within 15 years.2 The US Preventive Services Task Force additionally highlights the need to screen only those willing and able to undergo lung surgery,2,3 and all national guidelines recommend against screening those with poor baseline health status, whether quantified as less than 10 years’ life expectancy (American College of Chest Physicians),4 “life limiting comorbid conditions” (American Cancer Society),5 or “as long as patient functional status and comorbidity allow consideration for curative intent therapy” (National Comprehensive Cancer Network).6 Although national guidelines are consistent in recommending that baseline health should be considered prior to screening, how to define poor health is unclear, and the American Thoracic Society recognizes that there is an urgent need for more research in this area.7

9 February 2023 in AJPM Focus
Verified
Journal Article
Open access
ARAlison S. Rustagi
Alison S. Rustagi
ABAmy L. Byers
Amy L. Byers
JBJames K. Brown
James K. Brown
NPNatalie Purcell
Natalie Purcell
CSChristopher G. Slatore
Christopher G. Slatore
SKSalomeh Keyhani
Salomeh Keyhani
Veterans are at high risk for lung cancer and are an important group for lung cancer screening. Previous research suggests that lung cancer screening may not be reaching healthier and/or non-White individuals, who stand to benefit most from lung cancer screening. We sought to test whether lung cancer screening is associated with poor health and/or race and ethnicity among veterans. This cross-sectional, population-based study included veterans eligible for lung cancer screening (aged 55–79 years, ≥30 pack-year smoking history, current smokers or quit within 15 years, no previous lung cancer) in the 2017–2020 Behavioral Risk Factor Surveillance System surveys. Exposures were (1) poor health, defined as fair/poor health status and difficulty walking or climbing stairs, aligning with eligibility criteria for a pivotal lung cancer screening trial, and (2) race/ethnicity. The outcome was a receipt of lung cancer screening. All variables were self-reported. Of 3,376 lung cancer screening–eligible veterans representing an underlying population of 866,000 individuals, 20.3% (95% CI=17.3, 23.6) had poor health, and 13.7% (95% CI=10.6, 17.5) identified as non-White. Poor health was strongly associated with lung cancer screening (adjusted RR=1.64, 95% CI=1.06, 2.27); one third of veterans screened for lung cancer would not qualify for a pivotal lung cancer screening trial in terms of health. Marked racial disparities were observed among veterans: after adjustment, non-White veterans were 67% less likely to report lung cancer screening than White veterans (adjusted RR=0.33, 95% CI=0.11, 0.66). Lung cancer screening is correlated with poorer health and White race/ethnicity among veterans, which may undermine its population-level effectiveness. These results highlight the need to promote lung cancer screening, especially for healthier and/or non-White veterans, an important group of Americans for lung cancer screening.

4 September 2025 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
ARAlison S. Rustagi
Alison S. Rustagi
AJAbra M. Jeffers
Abra M. Jeffers
FGF. Julian Graham
F. Julian Graham
BCBeth E. Cohen
Beth E. Cohen
CSChristopher G. Slatore
Christopher G. Slatore
SKSalomeh Keyhani
Salomeh Keyhani
Background: Cannabis may cause chronic pulmonary disease. Prior studies have been limited by low cannabis exposure, lack of data on tobacco cigarettes, and/or limited numbers of those without tobacco cigarette use. Objective: To examine whether inhaled cannabis associated with asthma and chronic obstructive pulmonary disease, independent of tobacco cigarettes. Design: Cross-sectional analysis of population-based, nationally representative survey data. Participants: Adults 18–74 years who participated in the 2016–2020 Behavioral Risk Factor Surveillance System surveys. Main Measures: The exposure was past-30-day cannabis use, from 0 (0/30 days) to 1 (30/30 days). Outcomes were self-reported diagnoses by a medical professional of asthma or chronic obstructive pulmonary disease. We used multivariable logistic regression to test whether inhaled cannabis was associated with odds of disease, adjusted for sociodemographics and tobacco cigarette use (current/former/never). Pre-specified analyses restricted to those with no lifetime tobacco cigarette use. Key Results: Among n = 379,049, n = 23,035 reported inhaled cannabis use. Inhaled cannabis was associated with asthma overall (adjusted odds ratio (aOR) 1.44, 95% CI 1.26–1.63 for daily use) and among n = 221,767 with no lifetime tobacco cigarette use (aOR 1.51 for daily use, 95% CI 1.18–1.93). Inhaled cannabis was associated with chronic obstructive pulmonary disease overall (aOR 1.27 for daily use, 95% CI 1.10–1.46), with a non-significant elevated odds of disease among those with no lifetime tobacco cigarette use (aOR 1.54 for daily use, 95% CI 0.92–2.57). Conclusions: Inhaled cannabis was associated with asthma and chronic obstructive pulmonary disease after adjusting for tobacco cigarette use. Among those with no lifetime tobacco cigarette use, the association with asthma persisted. Cannabis may be a potential modifiable risk factor for asthma and chronic obstructive pulmonary disease.

28 May 2025 in American Journal of Preventive Medicine
Verified
Journal Article
Open access
EKEliana E. Kim
Eliana E. Kim
ICIrena Cenzer
Irena Cenzer
FGFrancis J. Graham
Francis J. Graham
JKJasmine Kang
Jasmine Kang
SLSei J. Lee
Sei J. Lee
ARAlison S. Rustagi
Alison S. Rustagi
Lung cancer screening with low-dose computed tomography (LDCT) reduces lung cancer mortality in the long term but carries immediate risks. Guidelines recommend screening persons whose life expectancy exceeds the screening test's time to benefit (TTB), defined as the time from screening initiation to first observed benefit. This study aimed to estimate the TTB for lung cancer screening to prevent lung cancer mortality. Randomized controlled trials of lung cancer screening with LDCT were identified from two prior systematic reviews and an updated search to December 3, 2023. Studies that reported lung cancer mortality were included. For each study, independent Weibull survival curves were fitted and Markov chain Monte Carlo simulations were generated to estimate the absolute risk reduction at different time points. Time to benefit was determined as the time at which absolute risk reduction thresholds (ARR=0.0005, 0.001, 0.002) were crossed. These estimates were pooled using a random-effects meta-analysis model. A total of eight randomized controlled trials comprising 88,526 participants were included. Enrollment age ranged from 50 to 70 years of age; follow-up duration ranged from 7.3 to 12.3 years. For every 1000 persons screened, 3.4 years (95% CI 2.2-5.1) passed before one death from lung cancer was prevented (ARR=0.001). The time to prevent one lung cancer death per 2000 persons screened (ARR=0.0005) was 2.2 years (95% CI 1.4-3.4); per 500 persons screened (ARR=0.002), it was 5.2 years (95% CI 3.7-7.3). Lung cancer screening is most appropriate for older adults at high risk of lung cancer with a life expectancy greater than 3.4 years.

4 February 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
ARAlison S Rustagi
Alison S Rustagi
CSChristopher Scott
Christopher Scott
SWStacey J Winham
Stacey J Winham
KBKathleen R Brandt
Kathleen R Brandt
ANAaron Norman
Aaron Norman
CVCeline M Vachon
Celine M Vachon
High alcohol intake and breast density increase breast cancer (BC) risk, but their interrelationship is unknown. We examined whether volumetric density modifies and/or mediates the alcohol-BC association. BC cases (n = 2233) diagnosed from 2006 to 2013 in the San Francisco Bay area had screening mammograms 6 or more months before diagnosis; controls (n = 4562) were matched on age, mammogram date, race or ethnicity, facility, and mammography machine. Logistic regression was used to estimate alcohol-BC associations adjusted for age, body mass index, and menopause; interaction terms assessed modification. Percent mediation was quantified as the ratio of log (odds ratios [ORs]) from models with and without density measures. Alcohol consumption was associated with increased BC risk (2-sided Ptrend = .004), as were volumetric percent density (OR = 1.45 per SD, 95% confidence interval [CI] = 1.36 to 1.56) and dense volume (OR = 1.30, 95% CI = 1.24 to 1.37). Breast density did not modify the alcohol-BC association (2-sided P > .10 for all). Dense volume mediated 25.0% (95% CI = 5.5% to 44.4%) of the alcohol-BC association (2-sided P = .01), suggesting alcohol may partially increase BC risk by increasing fibroglandular tissue.

7 March 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ARAlison S. Rustagi
Alison S. Rustagi
CSChristopher G. Slatore
Christopher G. Slatore
SKSalomeh Keyhani
Salomeh Keyhani